Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | November 08, 2013

The Hottest Topics and Technologies in Interventional Cardiology at TCT 2013

By Dave Fornell, DAIC editor

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting brought many new insights about the latest cardiovascular technologies and treatment techniques. Among the hottest topics were transcatheter heart valve repairs, renal denervation to treat drug resistant hypertension, left atrial appendage (LAA) occluders to prevent stroke and eliminate warfarin therapy in atrial fibrillation patients, bifurcation stenting trials and techniques, new insights on anti-clotting agents, increasing use of ultrasound and intravascular imaging, new technologies for FFR lesion assessments, and the latest stent trial data.

I offer my editor’s choice for the most innovative new technologies presented in sessions and on the show floor in a video format.

For a video of the top meeting highlights, Herb Aronow, M.D., offers his views on some of the most interesting topics discussed in sessions.

The most exciting interventional device to enter the U.S. market a couple days prior to TCT was Abbott's MitraClip. We conducted a video interview with the lead author of the MitraClip FDA pivotal trial at TCT.

Here is a summary of some of the top news from TCT. You can click on any item to read the full story.

CoreValve shows outcomes as good or better that Sapien

CT-FFR shown to be comparable to invasive FFR

Dedicated Tryton bifurcation stent did not meet primary endpoint

Provisional vs. two-stent bifurcation therapy has similar outcomes

Data promising for first FDA drug-eluting balloon trial

Simplified, non-adenosine iFR compares favorably with standard FFR

Hypothermia for STEMI safe, but did not reduce infarct size

Thrombectomy does not improve outcomes in NSTEMI PCI

MitraClip trial data leads to FDA approvalVideo interview with lead author of study

Bioresorbable polymer coated stent equal to traditional DES

Boston Scientific’s Lotus TAVR valve meets primary endpoints in REPRISE II

Pre-hospital bivalirudin for STEMI improves outcomes

• Data from two trials (ARCTIC-INTERRUPTION and OPTIMIZE) shows short-duration DAPT is feasible

Genetic profiling for CYP2C19 antiplatelet agents improves outcomes

Transradial access lowers bleeding risks in women

In addition to these news items, listed below are more top trial summaries and new product releases.

Related Content

Stryker Sustainability Solutions, Angiodynamics Soft Vu Omni Flush Angiographic Catheters, recall
News | Angiographic Catheter| July 25, 2016
Stryker Sustainability Solutions (formerly Ascent Healthcare Solutions) is recalling Angiodynamics Soft Vu Omni Flush...
Million Hearts Cardiovascular Disease Risk Reduction Model, CMS, reduce heart attacks and strokes, participants
News | Patient Engagement| July 22, 2016
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states,
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Absorb, bioresorbable stent, BVS
Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth revolution of inte
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
Sponsored Content | Videos | Inventory Management| July 19, 2016
You have bigger priorities than managing inventory.
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
Medtronic, In.Pact Admiral drug coated balloon, DCB, FDA approval, 150 mm length
Technology | Drug-Eluting Balloons| July 18, 2016
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon...
Overlay Init